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Abstract
Background: Systemic inflammation is linked to cardiovascular risk, but the influence of persistent pathogens,
which are conventionally dichotomously categorized, on circulating levels of inflammatory markers is not clear.
Antibody levels of pathogens have not been examined in relation to inflammation.
Methods: Using data from a subsample of the Multi-Ethnic Study of Atherosclerosis, we examined circulating
levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen in relation to five common persistent
pathogens: cytomegalovirus, herpes simplex virus-1, Hepatitis A virus, Helicobacter pylori and Chlamydia
pneumoniae. We tested the hypothesis that the number of seropositive pathogens (based on conventional cut-off
points) would not be as sensitive a marker of inflammation as immune response measured by antibody levels to
pathogens.
Results: High antibody response to multiple pathogens showed graded and significant associations with IL-6 (p <
0.001), CRP (p = 0.04) and fibrinogen (p = 0.001), whereas seropositive pathogen burden did not. In multiple linear
regression models, high antibody response to multiple pathogens maintained a positive association only with IL-6
(4.4% per pathogen exhibiting high antibody response, 95% CI 0.0-8.9).
Conclusions: High antibody response to pathogens was a more consistent marker of inflammatory outcomes
compared to seropositivity alone and high antibody response to multiple pathogens was a stronger marker
compared to any single pathogen.

Background
Persistent pathogens, those acquired early in life and
maintained without causing obvious illness, are impli
cated in cardiovascular disease etiology. Numerous stu
dies have suggested that persistent viruses such as
cytomegalovirus (CMV), herpes simplex virus-1 (HSV),
Hepatitis A virus (HAV) and bacterial pathogens such
as Helicobacter pylori (H. pylori) and Chlamydia pneu
moniae (C. pneumoniae) are associated with cardiovas
cular disease [1-4], although some studies do not
support a significant relationship [5-7]. Effects of
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multiple infectious agents may be synergistic, and some
authors suggest that pathogen burden (total number of
pathogens) has a greater impact on cardiovascular risk
than isolated pathogens [4,8,9]. It is hypothesized that
the association between pathogens and cardiovascular
disease is, in part, mediated through chronic activation
of inflammatory pathways [10,11].
In parallel to work linking chronic infections to ather
osclerosis, a number of studies have shown that various
markers of systemic inflammation are linked to cardio
vascular risk. Cytokines such as interleukin-6 (IL-6)
induce the production and secretion of acute-phase pro
teins including C-reactive protein (CRP) and fibrinogen
[12,13]. Chronic activation of these inflammatory path
ways is hypothesized to promote atherogenesis and
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thrombosis [14]. Levels of IL-6 [15,16], CRP [17-19] and
fibrinogen [20] show consistent associations with inci
dent coronary events and subclinical disease indepen
dent of established cardiovascular risk factors. A
number of risk factors for chronic inflammation (includ
ing smoking [21], physical activity [22], and obesity [23])
have been identified. However, the influence of persis
tent pathogens on circulating levels of inflammatory
markers is unclear and existing studies have been incon
sistent [24-26].
We used data from a large population-based sample to
examine associations between infectious agents and
inflammatory pathways implicated in cardiovascular dis
ease in healthy adults. We examined circulating levels of
IL-6, CRP and fibrinogen in relation to the presence of
and antibody response to five pathogens: CMV, HSV,
HAV, H. pylori and C. pneumoniae. We hypothesized
that the conventional definition of pathogen burden
(number of seropositive pathogens using conventional
cut-off points) would not be as sensitive a marker of
inflammation as an alternative definition also taking into
account antibody levels of pathogens.

Methods
Study sample

The Multi-Ethnic Study of Atherosclerosis (MESA) is a
population-based longitudinal study designed to investi
gate risk factors for atherogenesis. Study participants
(n = 6814), aged 45 to 84 years, were recruited from six
US communities and were free of clinical cardiovascular
disease at the time of the baseline visit from July 2000
to September 2002. The current cross-sectional analysis
uses data on C. pneumonia from the total cohort at
baseline, and from a sub-sample of 1000 randomly
selected cohort members who underwent serum testing
for additional pathogens implicated in cardiovascular
disease (CMV, HSV, HAV and H. pylori). Complete
information including data on all infectious agents,
inflammatory markers and covariables was available for
999 individuals. The Institutional Review Board at each
participating site reviewed the study and written
informed consent was collected from all participants.
Detailed methods and aims of the MESA cohort are
available [27].
Data

During the baseline visit, a range of sociodemographic,
behavioral and anthropometric variables were collected.
Data included education categorized into four groups
(less than high school, high school diploma or equiva
lent, some college or technical school and college
diploma); body mass index (BMI, kg/m2) to define over
weight or obesity status as ≥ 25 kg/m2; current alcohol
intake; pack-years of cigarette smoking, current use of
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medications known to alter inflammatory levels (any
one or more of the hormone replacement therapies,
aspirin, oral anti-inflammatory agents, lipid-lowering
drugs and non-steroidal anti-inflammatory drugs,
grouped into a single dichotomous variable); and selfrated health measured on a scale of 1 (best) to 5
(worst); 1-3 were considered “good self-rated health”.
Lab tests

Serum IgG antibodies to CMV, HSV, and H. pylori,
were measured by indirect enzyme immunoassay using
commercially available kits (DiaMedex Corp. Miami,
FL). The sensitivity and specificity of the tests ranged
from 94-100%. Hepatitis A antibody was measured
using the IMx HAVAB qualitative microparticle enzyme
immunoassay (Abbott Laboratories, Abbott Park, IL).
Immunoglobulin G antibodies to C. pneumoniae were
detected using a microimmunoflourescent antibody
assay with a range of 0-4 Microimmunofluorescence
(MIF) units (Focus Technologies, Cypress, CA). Conven
tional cut-off points were used to define dichotomous
seropositivity; equivocal values were classified as posi
tive. Individuals were considered seropositive for CMV
infection above 10.0 EU/mL, HSV infection above 16.0
EU/mL, HAV below a standardized calibrated rate, and
H. pylori infection above 0.90 EU/mL [28]. Infection
with C. pneumoniae was considered positive at 1 MIF
unit or higher. We defined ‘high antibody response’ to
pathogens as IgG values in the top quartile (lowest
quartile for HAV). For C. pneumoniae, titer groups 3-4
were considered high antibody response.
Interleukin-6 (pg/mL) was measured by ultrasensitive
ELISA (R&D Systems, Minneapolis, MN). CRP (mg/L)
and fibrinogen (mg/dL) were assessed by nephelometry
(BNII nephelometer, Dade Behring, Deerfield, IL). Ana
lytic coefficients of variation were 6.3%, 2.6%, and 3.6%
for IL-6, fibrinogen, and CRP, respectively.
Statistical methods

Descriptive analyses were carried out using chi-squared
tests (for trend where applicable). Kruskal-Wallis rank
tests were performed for descriptive variables with
skewed distributions. The dependent variables were cir
culating levels of IL-6 in pg/mL, CRP in mg/L and fibri
nogen in mg/dL. Interleukin-6 and CRP presented
skewed distributions and were log-normalized prior to
analysis. Independent variables took two forms: 1) sero
positive pathogen burden, defined as the count sum of
seropositive pathogens using conventional cut-off points
(0-5 pathogens with groups 0-1 collapsed for some ana
lyses); and 2) high antibody response to multiple patho
gens, defined as the count sum of pathogens with
antibody response in the highest quartile (high antibody
response to 0-5 pathogens, groups 3-5 collapsed for
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Chinese. Women comprised 57% of the sample. Eighteen
percent had finished high school but had no college edu
cation and 29% and 37% of participants had some college
education or completed college, respectively. Mean (SD)
BMI was 28.6 kg/m2 (5.6) and 72% were overweight or
obese. Almost 90% rated their health as good.
Nearly 77% of the sample was seropositive for CMV,
85% for HSV, 58% for HAV, 46% for H. pylori, and 71%
for C. pneumoniae. Less than 2% of the sample was
negative for all five of the tested pathogens, whereas
51% were seropositive for either four or five. Tetrachoric
correlation coefficients for seropositivity among patho
gens ranged between 0.42-0.55 except for those invol
ving C. pneumoniae, which were weaker and on the
order of 0.12-0.24. All were statistically significant at the
p < 0.05 level. Median (IQR) levels for IL-6, CRP, and
fibrinogen were 1.12 pg/mL (0.72-1.74), 2.00 mg/L
(0.82-4.59), and 340 mg/dL (296-391), respectively.
Table 1 shows the distribution of sociodemographic
and health characteristics of the 999-participant sample
according to number of seropositive pathogens. There
was a positive trend of increasing age by number of
pathogens. Non-whites and less educated individuals
had higher seropositive pathogen burden (both p <
0.001). Alcohol consumption was associated with lower
seropositive pathogen burden, as was self-rated good

some analyses). We first examined associations of inter
leukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen
with dichotomous measures of high antibody response
to each pathogen and second, with the number of
pathogens for which there was a high response (0-5).
We performed the same analysis using conventional
cut-offs for seropositivity to each pathogen and the
number of seropositive pathogens.
Tetrachoric (for dichotomous variables) correlation
coefficients were calculated to investigate correlations
between the different dependent variables and one-way
ANOVA was used to test for differences in inflamma
tory levels according to levels of markers. Linear regres
sion was used to estimate adjusted associations of
seropositivity and high antibody levels with inflamma
tory markers. Four levels of covariate adjustment were
used in regression models: 1) adjusted for age and sex;
2) adjusted for age, sex and race/ethnicity; 3) adjusted
for age, sex, race/ethnicity and education; and 4) adjusted
for all of the above plus body mass index, current
alcohol intake, cigarette smoking (pack-years), diabetes,
current use of medication and self-rated health.

Results
The mean age of the sample was 59 years (range 44-84),
with 46% white, 21% black, 23% Hispanic and 10%

Table 1 Mean (SD) or percent sociodemographic and health characteristics according to seropositive pathogen burden
in a sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002)
Number of seropositive pathogens

P value*

0-1

2

3

4

5

Age, y

56.8 (8.4)

59.1 (9.7)

59.5 (10.0)

59.9 (10.1)

59.9 (9.6)

0.02

Female

54.6

54.6

58.5

59.4

56.1

0.8

21.6
2.9

28.8
10.1

26.6
23.4

14.8
34.0

8.3
29.7

Race/ethnicity
White
Black

<0.001

Hispanic

1.7

3.9

12.9

35.3

46.1

Chinese

1.0

1.0

16.2

35.4

46.5

0.0

1.2

15.1

34.9

48.8

Education
<High school

<0.001

Finished high school

5.7

11.3

20.3

27.7

35.0

Some college

8.4

16.8

25.5

26.6

22.7

College graduate
BMI, kg/m2
Smoking, pack years

20.7
28.1 (5.4)

25.3
27.9 (5.3)

22.6
28.8 (6.1)

19.6
28.4 (5.5)

12.0
28.6 (5.7)

0.2

12.2 (30.6)

10.0 (17.1)

18.4 (30.1)

9.8 (18.8)

8.0 (14.4)

0.03
<0.001

Alcohol consumer

84.6

73.3

61.8

48.8

44.4

Diabetic

6.4

8.6

7.4

15.6

14.6

0.006

Self-rated good health

95.4

93.6

90.9

85.1

78.1

<0.001

N

110

163

217

256

253

–

Pathogens examined:
*P-values by chi-squared test. (sex, race/ethnicity, education, alcohol use, diabetes, self-rated health), chi-square test for trend (age and BMI), and Kruskal-Wallis
test (pack-years of smoking).
BMI: body mass index, kg/m2.
Alcohol consumer: alcoholic drink within the past week.
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health, whereas smoking and diabetes were associated
with a higher pathogen burden.
Table 2 shows inflammatory marker levels by seropo
sitivity and level of antibody response to each pathogen.
Seropositivity for individual pathogens was associated
with higher inflammatory levels for 11 of the 15 tested
associations (all except HAV with CRP and fibrinogen;
H. pylori with CRP; and C. pneumoniae with fibrinogen),
although only one (HSV with fibrinogen) was significant
(p = 0.006). HAV infection was significantly associated
with fibrinogen as well, but inversely. High antibody

response to multiple pathogens, on the other hand, was
consistently associated with higher inflammatory levels
across all markers, although only four (CMV with all
three markers and C. pneumonia with IL-6) were
significant.
Figures 1 and 2 show unadjusted inflammatory levels
by seropositive pathogen burden and high antibody
response to multiple pathogens, respectively. Seroposi
tive pathogen burden was associated with higher circu
lating levels of IL-6 and fibrinogen but the associations
were of borderline significance (p = 0.07 and 0.05 for

Table 2 Inflammatory marker levels by seropositivity and high antibody response to each pathogen in a sub-sample
of the Multi-Ethnic Study of Atherosclerosis (2000-2002)
Pathogen

Seropositivity* or
antibody response†

N

IL-6, pg/mL

CRP, mg/L

Fibrinogen,
mg/dL

Cytomegalovirus

Negative

227

1.07 (1.04)

1.90 (1.08)

345 (75)

Positive

758

1.18 (1.02)

2.01 (1.05)

349 (73)

-

0.06

0.5

0.5

Q1-Q3

510

1.13 (1.03)

1.83 (1.06)

344 (75)

Q4

249

1.31 (1.04)

2.44 (1.08)

360 (69)

-

0.004

0.002

0.002

Negative

150

1.05 (1.05)

1.67 (1.10)

333 (65)

Positive

835

1.18 (1.02)

2.04 (1.04)

351 (75)

-

0.05

0.06

0.006

600
248

1.15 (1.03)
1.24 (1.04)

2.02 (1.05)
2.09 (1.08)

350 (78)
353 (68)

P-value

P-value
Herpes simplex virus-1

P-value
Q1-Q3
Q4
P-value
Hepatitis A virus

Negative
Positive

0.7

0.4

2.02 (1.06)

353 (76)

574

1.17 (1.03)

1.95 (1.05)

342 (70)

0.6

0.7

0.02

Q2-Q4

319

1.13 (1.04)

1.85 (1.07)

348 (73)

Q1

255

1.21 (1.04)

2.10 (1.08)

357 (79)

-

0.2

0.2

0.2

Negative

531

1.13 (1.03)

1.99 (1.06)

347 (76)

Positive

454

1.18 (1.03)

1.97 (1.06)

350 (72)

-

0.3

0.9

0.5

Q1-Q3

215

1.17 (1.04)

1.96 (1.09)

347 (69)

Q4

246

1.20 (1.04)

1.98 (1.08)

352 (74)

-

0.7

0.9

0.5

288
697

1.14 (1.04)
1.16 (1.02)

1.90 (1.08)
2.02 (1.05)

349 (77)
347 (72)

P-value

P-value

P-value
C. pneumoniae

0.2
1.14 (1.03)

-

P-value

H. pylori

425

Negative
Positive

-

0.6

0.5

0.7

T1-T2

P-value

534

1.12 (1.03)

1.99 (1.05)

346 (72)

T3-T4

175

1.32 (1.06)

2.11 (1.11)

353 (72)

-

0.005

0.6

0.2

P-value

Presented as geometric mean (SE) for IL-6 and CRP; mean (SD) for fibrinogen.
Q1-Q4 represents lowest through highest quartiles for all pathogens except C. pneumoniae.
T1-T4 represents titer groups for C. pneumoniae.
P-values by one-way ANOVA.
*Cut-offs for seropositive status: cytomegalovirus≥ 8.0 Elisa Units (EU)/mL; herpes simplex virus-1 ≥ 16.0 EU/mL; hepatitis A virus, rate≤ 200; H. pylori≥ 0.90 EU/
mL; C. pneumoniae≥ 1.0 Microimmunofluorescence (MIF) units.
†
High antibody response defined as top quartile of antibody response to pathogen (lowest quartile for hepatitis A virus) and titer groups 3-4 for C. pneumoniae.
Low-intensity defined as bottom three quartiles to pathogens and titer groups 0-2 for C. pneumoniae..
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Figure 1 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by seropositive pathogen burden in a sub-sample of
the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression.

trend, respectively). There was no association with CRP.
The examination of associations of high antibody levels
with inflammatory markers revealed stronger patterns.
Levels of IL-6 (p < 0.001), CRP (p = 0.04) and fibrino
gen (p = 0.001) were all significantly and positively asso
ciated with high antibody response to multiple
pathogens.
Table 3 shows percent differences in inflammatory
markers associated with both methods of assessing
pathogen burden; seropositive pathogen burden and
high antibody response to multiple pathogens, respec
tively, in four sequentially adjusted models. Positive
associations between seropositive pathogen burden and
IL-6 and fibrinogen were modest in model 1 and not
statistically significant in adjusted models. In contrast,
high antibody response to multiple pathogens was posi
tively and significantly associated with IL-6, CRP and
fibrinogen in model 1, with a 2 to 9% increase in inflam
matory marker level per pathogen exhibiting a high anti
body response. Estimates weakened with further
adjustment, but associations with IL-6 remained statisti
cally significant after adjustment for age, sex, race/

ethnicity, and education (approximately 4% increase per
pathogen exhibiting a high antibody response; model 3).
Associations were reduced and no longer statistically
significant when further adjusted for BMI, behavioral,
and health variables (model 4).
Interactions of sex and race with pathogen burden
(according to seropositivity or high antibody response)
revealed no consistent patterns.

Discussion
This is among the first studies to evaluate the relation
ship between pathogen burden based on conventional
cut-offs for seropositivity and high antibody response as
potential correlates of multiple markers of inflammation.
We found that high antibody response was a more con
sistent marker of inflammatory outcomes than seroposi
tivity alone. Previous work has generally not
differentiated between seropositivity and antibody
response [29], but our results suggest that this may be
an important distinction. Earlier studies showed similar
associations with inflammation in many of the patho
gens examined here, suggesting that our results are

Figure 2 Levels of interleukin-6 (IL-6), C-reactive protein (CRP) and fibrinogen by high antibody response to multiple pathogens in a
sub-sample of the Multi-Ethnic Study of Atherosclerosis (2000-2002). P values for trend by linear regression.
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Table 3 Percent difference in inflammatory markers associated with increasing seropositive pathogen burden* and
increasing number of pathogens exhibiting high antibody response† in a sub-sample of the Multi-Ethnic Study of
Atherosclerosis (2000-2002)
Method

Inflammatory marker

Model 1

Model 2

Model 3

Model 4

Seropositive pathogen burden*

IL-6

2.2 (-0.9,5.3)

0.7 (-2.9,4.4)

-1.4 (-5.0,2.4)

-2.6 (-6.0,0.9)

CRP

1.4 (-4.1,7.2)

0.5 (-5.9,7.3)

-2.0 (-8.4,4.9)

-4.2 (-10.1,2.0)

Fibrinogen

0.7 (-0.3,1.6)

-1.2 (-2.3,0.0)

-1.6 (-2.7,-0.5)

-1.7 (-2.8,-0.6)

IL-6

9.3 (4.9,13.8)

5.8 (1.5,10.3)

4.4 (0.0,8.9)

1.7 (-2.4,6.0)

CRP

8.0 (0.2,16.4)

4.3 (-3.3,12.5)

2.2 (-5.3,10.4)

-0.2 (-7.3,7.4)

Fibrinogen

2.0 (0.7,3.3)

0.7 (-0.6,2.0)

0.4 (-0.9,1.8)

0.2 (-1.1,1.5)

High antibody response to multiple pathogens†

*Seropositive pathogen burden: seropositivity to 0-5 pathogens analyzed as a continuous variable.
†
High antibody response to multiple pathogens: high antibody response to 0-5 pathogens analyzed as a continuous variable.
Coefficient (95% CI) shows the percent difference in inflammatory marker level per additional seropositive pathogen or per additional pathogen exhibiting a high
antibody response.
Model 1 adjusted for age and sex.
Model 2 adjusted for age, sex and race/ethnicity.
Model 3 adjusted for age, sex, race/ethnicity and education.
Model 4 adjusted for all of the above plus body mass index, alcohol intake, smoking (pack years), diabetes, medications, self-rated health.

compatible with population based estimates [8,26,30-32].
Also in line with previous findings, sociodemographic
and health indices were significantly associated with
number of seropositive pathogens [28,33-35]. There are
less data, however, showing the relationships between
sociodemographic characteristics and antibody response
in population based studies in the US.
Testing of persistent pathogens often relies on enzyme
linked immunosorbent assays (ELISA). These assays
provide a qualitative assessment of the amount of anti
body in a serum sample. Clinical studies are generally
concerned with whether or not individuals tests positive
for IgM or IgG to the pathogen of interest and rarely
provide data on the qualitative antibody response identi
fied in the ELISA test. Our findings regarding associa
tions of antibody response with inflammation suggests
that the qualitative data obtained from an ELISA is an
important variable given that this measure predicts
inflammation levels. Our findings suggest that antibody
levels among the infected, rather than seropositivity is a
better marker of inflammatory levels.
Pathogen burden (number of seropositive pathogens)
was more strongly associated with inflammation than
was any one individual pathogen and seropositivity to
pathogens was highly correlated. Pathogen burden has
been implicated in cardiovascular disease in several dif
ferent study populations [33,36]. It has been suggested
that pathogen burden may not only be a predictor of
coronary complications, as previously described, but that
it may also be associated directly with the development
of atherosclerotic plaques [24]. Zhu and colleagues have
suggested that inflammation is one pathway by which

these associations are linked [8]. Prasad et al. found that
pathogen burden and CRP levels interacted significantly
such that carriers of 4-5 pathogens and elevated CRP
levels (> 0.5 mg/dL) had higher odds of coronary artery
disease compared to those with fewer pathogens [4],
supporting the notion that pathogen burden along with
inflammation has a stronger impact than any one patho
gen alone or inflammation alone. A recent study showed
that antibody levels to one of the pathogens we exam
ined here, CMV, was associated with an increased rate
of cardiovascular mortality among aging individuals
[37]. No previous studies have examined the impact of
high antibody response to multiple pathogens on inflam
matory outcomes.
We found that associations of antibody levels with
IL-6 were more consistent than associations with the
other inflammatory markers. In addition, associations
with IL-6 persisted after adjustment for age, race and
socioeconomic factors but were reduced and no longer
statistically significant after adjustment for potential
mediators of inflammation such as smoking and obesity.
Limited sample size, as well as strong associations
between antibody levels and variables such as BMI and
smoking may have hampered our ability to detect asso
ciations after multiple adjustments. Larger studies are
needed to determine whether associations are indepen
dent of other risk factors.
There are several possible pathways by which high
antibody response to multiple pathogens could impact
inflammation more strongly than seropositivity alone.
Infection with a particular pathogen may not strongly
influence a disease process whereas a strong immune
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response to that pathogen may. Rheumatic heart disease
is an example of this phenomenon whereby the immune
response to the pathogen (and ensuing inflammation) is
the relevant disease process, rather than the infection
itself [38]. In the case of infections occurring early in
life and persisting over time (likes several of the patho
gens we studied); a higher initial infectious dose may
lead to a more vigorous antibody response at a young
age which is maintained over the life course for persis
tent infections. Since persistent infections are generally
acquired early in life [39], the long term effects of high
antibody response may lead to chronically higher levels
of inflammation. However, it is not clear why individuals
exhibit differentials in antibody response to pathogens.
Recent work has indicated that lower socioeconomic
position and exposure to chronic stressors may lead to a
higher antibody response to CMV, HSV, and H. pylori
[28,40]. Indeed, there are several experimental studies
that have demonstrated significant relationships between
exposure to psychosocial stressors and a high antibody
response to persistent herpes virus (see Herbert and
Cohen 1993 for review). Thus, a number of host charac
teristics may influence antibody response to an infec
tion. Additional studies are needed to better understand
the mechanisms by which antibody response may influ
ence systemic inflammation over the life course.
Some methodological considerations of this study war
rant mention. Relatively small sample sizes may have
affected our ability to detect associations with all mar
kers. The inflammatory outcomes we tested could have
been influenced by a number of factors that were not
measured or measured imprecisely, even though care
was taken to account for several potentially inflamma
tory conditions and medications that may impact
inflammation. Our models also did not account for
recent or current acute inflammatory states, such as
those associated with the common cold, which may
have impacted our findings. Antibody and biomarker
levels were only measured once and intra-individual var
iation cannot be accounted for. However, assay variabil
ity would be expected to bias findings towards the null
so the observed associations are potentially underestima
tions. Also, IgG antibody response provides data on past
infection- we did not examine data on recent infection
or DNA shedding of the viruses and cannot assess
whether individuals were experiencing reactivation of
the infection. The cross-sectional nature of this analysis
precludes implications of causality, and specifically, we
cannot rule out the possibility that higher inflammatory
status may have led to higher levels of antibodies via
activation of the immune response. Four racial/ethnic
groups were represented in our data, adding an impor
tant strength to our study; however, findings may not be
representative of other ethnic or age groups. Finally, it is
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important to note that viral and bacterial infectious
agents may act through different mechanistic pathways
to impact inflammation, but assessment of alternative
biological pathways, such as infection residing within
the cardiovasculature, was beyond the scope of this
cross-sectional observational study.

Conclusions
In summary, high antibody response to multiple patho
gens emerged as a better marker of inflammation com
pared to seropositivity status alone. Our findings suggest
that future studies should consider including antibody
response data in addition to seropositivity classification
of pathogens. Technological advances for refining mea
surement of antibody response for persistent pathogens
is an important endeavor and may reduce measurement
error in this potentially important biomarker. Opportu
nities for further research also include examination of
the mechanistic pathways by which antibody response
to pathogens contributes to inflammation as well as to
cardiovascular disease and its correlates.
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